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Abstract
Background—Phthalates are hypothesized to cause obesity, but few studies have assessed 
whether prenatal phthalate exposures are related to childhood body mass index (BMI).
Methods—We included 707 children from three prospective cohort studies enrolled in the United 
States between 1998 and 2006 who had maternal urinary phthalate metabolite concentrations 
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measured during pregnancy, and measures of weight and height at ages 4 to 7 years. We calculated 
age- and sex-standardized BMI z-scores and classified children with BMI percentiles ≥85 as 
overweight/obese. We used mixed effects regression models to estimate associations between a 1-
standard deviation increase in natural log phthalate metabolite concentrations and BMI z-scores 
and overweight/obesity. We estimated associations in multiple metabolite models adjusted for 
confounders, and evaluated heterogeneity of associations by child’s sex, race/ethnicity, and cohort.
Results—Mono-3-carboxypropyl phthalate (MCPP) concentrations were positively associated 
with overweight/obese status in children (odds ratio [95% credible interval] = 2.1 [1.2, 4.0]) but 
not with BMI z-scores (beta = −0.02 [−0.15, 0.11]). We did not observe evidence of obesogenic 
effects for other metabolites. However, monoethyl phthalate (MEP) and summed di-(2-ethylhexyl) 
phthalate metabolites (∑DEHP) concentrations were inversely associated with BMI z-scores 
among girls (MEP beta = −0.14 [−0.28, 0.00]; ∑DEHP beta = −0.12 [−0.27, 0.02]).
Conclusions—Maternal urinary MCPP, a non-specific metabolite of several phthalates, was 
positively associated with childhood overweight/obesity. Metabolites of diethyl phthalate and 
DEHP were associated with lower BMI in girls but not boys, suggesting prenatal exposures may 
have sexually dimorphic effects on physical development.
Introduction
One out of three children aged 2 to 19 years in the United States is overweight or obese.1 
Obese children have poorer physical and psychosocial health compared to their normal-
weight peers and exhibit early physiologic changes associated with chronic health 
conditions.2 While energy balance is a key determinant of weight change, the 
“environmental obesogen” hypothesis posits that prenatal exposure to endocrine disrupting 
chemicals, including phthalates, may also increase obesity risk by altering adipogenesis and 
lipid homeostasis.3
Phthalates are industrial chemicals with endocrine disrupting properties and widespread 
human exposure.4 Low molecular weight phthalates are used as solvents in products such as 
cosmetics, fragrances, and medications.5 High molecular weight phthalates enhance 
flexibility and durability of plastics and are found in building materials and food packaging.5 
Urine is the optimal matrix for measurement of phthalates, which are rapidly transformed to 
polar metabolites that are eliminated by urinary excretion.6
Detection of phthalate metabolites in amniotic fluid and breast-milk demonstrate the 
potential for early life exposures4 and prenatal exposures to certain phthalates have been 
associated with reproductive and developmental outcomes in children.7 Some phthalates 
exhibit anti-androgenic activity in animals4 and human studies have reported sex differences 
in associations of phthalate exposures with child health.7 Furthermore, early life phthalate 
exposures may alter metabolic and homeostatic mechanisms related to the development of 
obesity.3 Toxicologic studies have demonstrated that certain phthalates affect steroid 
hormone levels and interfere with peroxisome proliferator-activated receptors, which 
regulate lipid metabolism and adipogenesis.8
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Valvi et al.9 reported associations of maternal urinary summed di-(2-ethylhexyl) phthalate 
(∑DEHP) metabolites with higher body mass index (BMI) in girls but lower BMI in boys in 
a Spanish birth cohort. In the Mount Sinai Children’s Environmental Health and Disease 
Prevention Research Center (MSSM), Buckley et al.10 reported associations of maternal 
urinary ∑DEHP metabolite concentrations with lower percent fat mass in children with no 
differences in associations between girls and boys, though the study was underpowered to 
identify sex differences. Because animal studies suggest that certain phthalates exhibit 
sexually dimorphic effects,4 we pooled the MSSM cohort with two additional birth cohorts 
in the United States to examine associations of prenatal urinary phthalate metabolite 
concentrations and BMI assessed in children between ages 4 and 7 years and evaluated 
differences by child’s sex.
Methods
Children’s Environmental Health Center cohorts
The MSSM study enrolled 479 primiparous women with singleton pregnancies from the 
Mount Sinai prenatal clinic and two adjacent private practices in New York City between 
1998 and 2002. Women delivered at the Mount Sinai Medical Center. Seventy-five women 
were subsequently excluded for reasons described elsewhere.11 The final cohort consists of 
404 mother-infant pairs for whom birth data were available.
The Columbia Center for Children’s Environmental Health (CCCEH) enrolled 727 pregnant 
women between 1998 and 2006. The cohort was restricted to non-smoking women 18–35 
years old who self-identified as either African American or Dominican and who had resided 
in Northern Manhattan or the South Bronx in New York City for >1 year prior to pregnancy. 
Additional details of the study population have been previously reported.12
The Health Outcomes and Measures of the Environment (HOME) Study, a prospective birth 
cohort located in Cincinnati, Ohio, enrolled 468 women between 2003 and 2006. Because 
the HOME Study contains a nested, randomized trial of in-home lead and injury hazard 
controls women had to be living in housing built before 1978. Additional eligibility criteria 
and study population characteristics have been described elsewhere.13 A total of 389 women 
delivered live-born, singleton infants without birth defects.
Questionnaires were administered to each mother at study enrollment to ascertain maternal 
characteristics including age at delivery, race/ethnicity, education, work status during 
pregnancy, parity, height, and pre-pregnancy BMI. We calculated gestational weight gain as 
last pregnancy weight minus self-reported pre-pregnancy weight. Women provided a spot 
urine sample at mean ± standard deviation (SD) gestational ages of 31.6 ± 5.1 (MSSM), 34.4 
± 3.0 (CCCEH), and 27.1 ± 2.2 (HOME) weeks. Child’s sex was ascertained from birth 
records and breastfeeding status of the index children was assessed by questionnaire.
For MSSM, we determined maternal smoking during pregnancy based on self-report. For the 
HOME Study, we classified women as active smokers during pregnancy if the average of 
three maternal cotinine serum concentrations (measured twice during pregnancy and at 
birth) exceeded 3 ng/mL.14 CCCEH excluded women with evidence of active smoking.12
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Human subjects
Women provided informed consent prior to participation and children aged ≥ 7 years 
provided assent. The MSSM, CCCEH, and HOME studies received approval from the 
Institutional Review Boards (IRBs) of the Mount Sinai School of Medicine (MSSM), 
Columbia University (CCCEH), and the University of Cincinnati College of Medicine 
(HOME), respectively. The Centers for Disease Control and Prevention (CDC) IRB relied on 
the determinations made by the other IRBs for the CCCEH and HOME studies. For MSSM, 
the involvement of the CDC laboratory was determined not to constitute engagement in 
human subjects research. The current analysis was approved by the IRB of the University of 
North Carolina at Chapel Hill.
Phthalates exposure assessment
All spot urine samples were analyzed by CDC staff for monoethyl phthalate (MEP), mono-
n-butyl phthalate (MnBP), mono-isobutyl phthalate (MiBP), mono(3-carboxypropyl) 
phthalate (MCPP), monobenzyl phthalate (MBzP), mono(2-ethylhexyl) phthalate (MEHP), 
mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate 
(MEOHP), and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP). Analytic methods and 
quality control procedures have been described.15,16 For each metabolite, we replaced values 
below the limit of detection (LOD) by the LOD/√2. We examined DEHP metabolites 
(MECPP, MEHHP, MEHP, MEOHP) as a micromolar sum (ΣDEHP, micromoles per 
liter).11 To facilitate effect size comparison, we standardized the natural log concentration of 
each phthalate metabolite or sum to its mean and SD in the pooled sample.
Outcome assessment
Weight and height were measured at follow-up visits scheduled for approximately ages 4–
5.5, 6, and 7–9 years (MSSM), 5 and 7 years (CCCEH), and 4, 5, and 7–9 years (HOME). 
We measured children in bare or stocking feet while wearing light clothing (i.e., pediatric 
gown, underwear, or shorts and a t-shirt). We assessed weight using a digital scale (all 
HOME visits and CCCEH 5 year visit) or a pediatric Tanita scale (all MSSM visits and 
CCCEH 7 year visit) (models TBF-300 and BC-418, Tanita Corporation of America, 
Arlington Heights, Illinois) and determined height using wall-mounted stadiometers. We 
calculated BMI [weight (kg) / height (m)2], which is a moderately sensitive and highly 
specific indicator of adiposity, as a measure of excess weight for height.17 We computed 
age- and sex-standardized z-scores and percentiles for BMI using a CDC macro.18 We 
classified children as overweight/obese at each follow-up visit if their age- and sex-
standardized BMI percentile was ≥85, which corresponds to a BMI z-score of approximately 
1.
Statistical analysis
The current analysis includes infants of singleton pregnancies who were born at ≥32 weeks 
gestation and ≥1,500 grams and had measured prenatal maternal urinary phthalate 
metabolite concentrations. After excluding very dilute urine specimens due to the potential 
for inaccurate biomarker measurements (<10 mg/dL creatinine, n = 9),11 1,143 children met 
our baseline inclusion criteria. To examine BMI prior to puberty and ensure overlap in age 
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assessments among cohorts, we further restricted the sample to children with weight and 
height data collected at one or more follow-up visits occurring between 4 and 7 years of age 
(N=707; 1,416 follow-up visits).
We assessed associations of prenatal urinary phthalate metabolite concentrations with body 
size using a Bayesian modeling framework to (1) account for missing at random covariate 
data, (2) stabilize estimates of correlated metabolites, and (3) conduct sensitivity analyses 
for potentially nonignorable (i.e., missing not at random) loss to follow-up.
MSSM and HOME measured creatinine to account for urinary dilution. CCCEH measured 
specific gravity in all urine samples (n = 339), with creatinine additionally measured in a 
subset (n = 202). In the subset with both measures, the Pearson correlation coefficient 
between creatinine and specific gravity was 0.78. To obtain a common measure of urine 
dilution, we predicted missing natural log creatinine concentrations in CCCEH at each 
iteration of the Markov Chain Monte Carlo (MCMC) algorithm in our Bayesian models 
using a linear regression model. We also used our Bayesian framework for multiple 
imputation of breastfeeding status (n = 6), maternal pre-pregnancy BMI (n = 58), and 
gestational weight gain (n = 107) assuming values were missing at random (see eAppendix).
To account for potential confounding among correlated phthalate metabolites, we estimated 
associations in multiple metabolite Bayesian hierarchical models.19 Following standard 
practice, the beta coefficient for each standardized phthalate metabolite was given an 
independent, normally distributed prior distribution with a mean of zero and variance of 
1/τ2. We set τ = 1, which represents a prior belief that 95% of the effects of a SD difference 
in natural log phthalate metabolite concentration are within an odds ratio (OR) of 0.14 to 7.1 
for overweight/obese status or approximately ± two SDs of the mean BMI z-score 
distribution in the study sample. Similarly, we specified independent, null-centered priors 
with τ = 1 for beta coefficients of covariates included in outcome and imputation models.
We estimated associations per SD increase in natural log phthalate metabolite concentrations 
in logistic and linear mixed effects models with random intercepts to account for multiple 
observations per child. Within our Bayesian framework, point and interval estimates were 
estimated as posterior mean ORs and beta coefficients and their associated 95% credible 
intervals (CI). CIs are more easily interpreted than confidence intervals from a traditional 
analysis: given the data and the model, there is a 95% chance that the true value is within 
this interval.
A priori, we chose variables to include in our final models that were either identified as 
potential confounders using directed acyclic graphs or were expected to be strong predictors 
of the outcome but not on the causal pathway. While we included a large number of 
covariates, our Bayesian framework stabilized estimates and protected against variance 
inflation using weakly informative prior information. Potential confounders included cohort, 
maternal race/ethnicity, maternal age at delivery, maternal education, maternal work status 
during pregnancy, maternal pre-pregnancy BMI, gestational weight gain, maternal smoking 
during pregnancy, calendar date of urine collection, and parity. Predictors of body size in 
children included maternal height, child’s sex, breastfeeding of the index child, and months 
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of age at follow-up. Due to uncertainty regarding how best to account for urine dilution,20,21 
we compared results with and without creatinine adjustment in preliminary models and 
found no important differences. Therefore, we accounted for urine dilution by including 
natural log creatinine as a covariate.20 To improve fit of BMI z-score models, we adjusted 
for an interaction between child’s sex and age at follow-up because outcome distributions by 
age differed between girls and boys. Continuous covariates were standardized to twice the 
population SD22 and we included a quadratic term for maternal pre-pregnancy BMI and 
cubic terms for maternal age and gestational weight gain based on their non-linear 
associations with outcomes.
We examined effect measure modification by cohort, child’s sex, and race/ethnicity by 
including interaction terms between the modifier and each metabolite concentration. In 
models assessing modification by both cohort and either sex or race/ethnicity, we included 
all two- and three-way interaction terms between metabolites, cohort, and the covariate. 
When assessing modification by race/ethnicity, we excluded children of “other race” in all 
cohorts and Hispanic children in HOME due to small numbers. We considered there to be 
meaningful effect modification if the 80% CI for the interaction term did not cross the null 
value (similar to an alpha of 0.2 in a frequentist framework). Finally, we explored dose-
response relationships using restricted quadratic splines.23
In sensitivity analyses, we compared associations estimated in multiple metabolite models to 
those estimated in models including only one metabolite at a time, a common approach that 
may result in confounding by correlated metabolites. Single metabolite models specified the 
same prior distributions for phthalate beta coefficients as the main analyses, i.e. β ~ N(0,1).
Additionally, we conducted a sensitivity analysis for loss to follow-up due to concern that 
the probability of follow-up visit attendance may depend on a child’s outcome value at the 
time. Our primary models included children with at least one follow-up visit (N=707) under 
the assumption that outcome data are missing at random. We compared these results to a 
selection model approach24 that included all children with measured prenatal phthalate 
metabolite concentrations (N=1,143) under a potentially nonignorable (missing not at 
random) missing data mechanism. For this analysis, we constructed a binary missing 
outcome indicator variable for attendance at each follow-up visit based on the cohort-
specific visit schedules (0 if observed, 1 if missing). Within our MCMC algorithm, we 
jointly fit the outcome model with cohort-specific models for the missing outcome indicator 
to allow predictors of missingness to vary by cohort. We specified the missing outcome 
indicator models as logistic mixed effects regression models with random intercepts, 
dependent on the outcome (potentially unobserved), maternal age, race/ethnicity, maternal 
education, maternal pre-pregnancy BMI, birthweight, child’s sex, calendar date of urine 
collection, and age (months) at follow-up. The CCCEH missing outcome indicator model 
additionally included four variables that were unmeasured in the other cohorts but 
previously reported to predict subject retention in CCCEH (receipt of public assistance 
during pregnancy, maternal satisfaction with living conditions, neighborhood poverty rate, 
and Spanish language linguistic isolation).25 Finally, because selection models are sensitive 
to unverifiable assumptions underlying the specification of the missing data model, we 
varied the parameterization of the missing outcome indicator models by using different 
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functional forms for continuous variables, fitting a single missing indicator model for all 
three cohorts, and including interaction terms between age at follow-up and child’s sex and 
race/ethnicity.
We conducted descriptive analyses in SAS version 9.3 (SAS Institute, Cary, NC). We ran 
Bayesian models in WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) with 
a 10,000 iteration burn-in followed by 50,000 additional iterations. We ran ten chains for 
inference from the MCMC procedure for our sensitivity analyses for nonignorable missing 
data. We assessed model convergence using standard diagnostic measures.22
Results
The distributions of participant characteristics by cohort illustrate differences in the 
inclusion criteria and source populations of each study (Table 1). For example, HOME 
enrolled primarily white, non-Hispanic mothers who were older and had more years of 
education than women in the New York City cohorts. Mean (SD) maternal heights (cm) 
were 64 (2.9), 64 (2.8), 65 (2.8), and 64 (2.9) in MSSM, CCCEH, HOME, and the pooled 
sample, respectively.
Except for MEHP, the hydrolytic metabolite of DEHP, urinary phthalate metabolite 
concentrations were detectable in ≥95% of urine samples (see eTable 1). Although 
geometric mean urinary phthalate metabolite concentrations were lower in HOME than 
among MSSM and CCCEH participants, concentration distributions exhibited substantial 
overlap (see eTable 1). Spearman rank correlations among concentrations of phthalate 
metabolites in the study sample ranged from 0.37 for MEP and ∑DEHP to 0.78 for MnBP 
and MiBP. The percent of children classified as overweight or obese at all ages was lower in 
HOME than in the other two cohorts (Table 2). Similarly, mean age- and sex- standardized 
BMI z-scores were highest among CCCEH children and lowest in HOME (see eTable 2).
Adjusted associations of prenatal urinary phthalate metabolite concentrations with 
overweight/obese status and age- and sex-standardized BMI z-scores are reported in Table 3 
(overall and by child’s sex) and Table 4 (by race/ethnicity). MCPP was associated with 
increased odds of overweight/obese status (OR [95% CI] = 2.1 [1.2, 4.0]). The association 
was stronger among Hispanic children compared to non-Hispanic black or white children 
(Figure 1). In contrast, MCPP was not associated with age- and sex- standardized BMI z-
scores (beta = −0.02 [−0.15, 0.11]). We observed modification of the associations of MEP, 
MnBP, and ∑DEHP with BMI z-scores by child’s sex. MEP was associated with lower BMI 
z-scores among girls (beta = −0.14 [−0.28, 0.00]) but not boys (Figure 2). ∑DEHP was also 
associated with lower BMI z-scores among girls (beta = −0.12 [−0.27, 0.02]) whereas MnBP 
was associated with higher BMI z-scores among girls (beta = 0.16 [−0.06, 0.39]), though 
95% CIs for sex-specific associations crossed the null value (Table 3).
Spline models assessing the shape of relationships between prenatal urinary phthalate 
metabolite concentrations and outcomes were consistent with null associations or a linear 
dose-response trend for all metabolites and outcomes (not shown). For example, the odds of 
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overweight/obese status increased linearly with increasing MCPP concentration whereas the 
association of MCPP with BMI z-scores was null (see eFigure1).
Cohort-specific associations are reported in eTable 3 and eTable 4. Associations with 
overweight/obese status were not modified by cohort, though CIs for individual cohorts were 
wide. For example, ORs (95% CIs) for the association of MCPP with overweight/obese 
status were 2.2 (0.88, 5.3) in MSSM, 2.6 (1.1, 6.4) in CCCEH, and 1.3 (0.41, 4.5) in HOME. 
Cohort modified associations of two metabolites, MnBP and MEP, with BMI z-scores such 
that beta coefficients were on the opposite sides of the null in MSSM compared to CCCEH 
and HOME. However, MSSM was the smallest cohort and CIs were imprecise.
Point and interval estimates of most associations were similar whether estimated in single or 
multiple metabolite models (see eTable 5). However, the association between urinary MCPP 
concentrations and overweight/obese status was attenuated toward the null in the single (OR 
= 1.4 [0.88, 2.3]) compared to the multiple (OR = 2.1 [1.2, 4.0]) metabolite model. Our 
sensitivity analysis for loss to follow-up indicated that children with higher BMI z-scores 
were more likely to be followed-up. However, associations between prenatal phthalate 
concentrations and overweight/obese status and BMI z-scores were similar whether or not 
we accounted for potentially nonignorable missing outcomes (see eTable 5). Findings were 
comparable in models with alternative specifications of the missing outcome indicator model 
(not shown).
Discussion
In this pooled analysis of three birth cohorts, each SD increase in prenatal urinary 
concentrations of MCPP was associated with greater than twice the odds of overweight or 
obesity among 4 to 7 year old children. MCPP is a non-specific metabolite of several high 
molecular weight phthalates (e.g., di-isooctyl phthalate, di-n-octyl phthalate (DnOP), di-
isononyl phthalate, di-isodecyl phthalate) and a minor metabolite of dibutyl phthalate 
(DBP).26 We also observed inverse associations of prenatal concentrations of MEP, the main 
metabolite of diethyl phthalate (DEP), and ∑DEHP with BMI z-scores among girls.
Three prospective studies have assessed early life phthalate exposures and childhood 
adiposity.9,10,27 In a small Dutch study utilizing infant cord blood measures of oxidative 
DEHP metabolites, high cord blood concentrations of one metabolite, MEOHP, were 
inversely associated with BMI among infant boys.27 However, phthalate concentrations 
measured in cord blood are susceptible to contamination6 and may arise from hospital-based 
exposures to DEHP at delivery.28 Valvi et al.9 assessed associations between the average of 
first and third trimester maternal urinary summed low (∑LMWP: MEP, MnBP, MiBP) and 
high (∑HMWP: MBzP and 4 DEHP metabolites) molecular weight phthalate metabolites 
concentrations and childhood anthropometry in a Spanish birth cohort study. ∑HMWP 
metabolites concentrations were associated with weight gain z-scores in the first 6 months 
and BMI z-scores at ages 1, 4, and 7 years in a sex-specific manner (lower among boys, 
higher among girls), and supplemental analyses indicated stronger associations for ∑DEHP 
than MBzP. ∑LMWP metabolite concentrations were not associated with outcomes and 
MCPP was not assessed. In a previous analysis of the MSSM cohort,10 children in the 
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highest tertile of third trimester urinary ∑DEHP concentrations had lower percent fat mass 
than children in the first tertile. Other metabolites were not associated with percent fat mass 
and there was no evidence of sex-specific effects, though the study had limited sample size.
We evaluated heterogeneity of associations by child’s sex because development of body fat 
differs between girls and boys, and certain phthalates, including DEHP and DBP, exhibit 
anti-androgenic activity.4 In the current study, ∑DEHP was inversely associated with BMI z-
scores among girls but not boys. The previous Spanish study, where prenatal urinary 
concentrations of DEHP metabolites were higher, reported inverse associations of ∑DEHP 
with body size among boys but positive associations among girls.9 Studies of high dose 
postnatal DEHP exposure in rodents have reported reductions in body weight mediated by 
peroxisome-proliferator activated receptor alpha.29,30 However, animal studies of early life 
DEHP exposures report effects on body weight that depend on timing, dose, and 
species31–35 with only one study reporting notable sex differences.33
We also observed sexual dimorphism for metabolites of DBP (MnBP) and DEP (MEP), 
which have not been assessed as potential obesogens in animal studies. As DEP does not 
produce anti-androgen effects4 it has been asserted that associations of its metabolite MEP 
with outcomes related to androgen insufficiency in human studies may be due to its 
correlation with other phthalates.4 Our associations were co-adjusted but could have been 
confounded by phthalates not measured in this study or other endocrine disrupting chemicals 
contained in personal care products. Alternatively, DEP may be related to sex differences in 
other pathways related to development, such as effects on thyroid hormones.
Ashley-Martin et al.36 assessed associations of first trimester urinary phthalate metabolite 
concentrations with cord blood levels of two adipocyte-produced hormones. They reported 
associations of MCPP, but not other phthalate metabolites, with leptin and adiponectin 
levels. Female infants in the highest quartile of MCPP concentrations had higher odds of 
high adiponectin (OR = 2.9, 95% CI = 1.0, 7.8) while male infants in all quartiles of MCPP 
concentrations had higher odds of high leptin compared to the lowest quartile. Because early 
childhood adiposity has been positively associated with cord blood adiponectin 
concentrations and negatively associated with cord blood leptin,37 these sexually-dimorphic 
associations are consistent with our finding of a stronger association of MCPP 
concentrations with overweight/obesity among girls than boys.
We observed an association of MCPP with overweight/obese status but not with differences 
in continuous BMI z-scores. BMI does not distinguish between lean and fat mass, whereas 
classifying individuals as overweight or obese identifies those at the high end of the BMI 
distribution who are more likely to have excess body fat.17 In children, use of BMI cut 
points to identify those with excess body fat is moderately sensitive and highly specific.17 
Consequently, the association of MCPP with overweight/obese status, but not BMI z-scores, 
may reflect that BMI is a less sensitive marker of adiposity or that MCPP exposures are 
associated only with changes in the upper end of the BMI z-score distribution. Future 
analyses could examine associations of MCPP with the full distribution of BMI rather than 
assessing changes in the population mean (for example, using quantile regression).
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Like DEHP, DnOP and other high molecular weight phthalates are used in plastics such as 
food packaging.38 The strongest predictor of childhood overweight is maternal 
overweight,39 and we adjusted for maternal pre-pregnancy BMI and gestational weight gain 
to control for potential confounding through shared maternal and child diet. We lacked 
information on diet and cannot rule out confounding by dietary sources of a woman’s 
phthalate exposures that may also be related to obesity in her child. Urinary concentrations 
of MCPP and DEHP metabolites have been associated with consumption of similar foods 
(meat, diary, and other fatty foods),38 suggesting that any confounding of the MCPP and 
∑DEHP associations with body fatness would be in the same direction. Therefore, the 
inverse association of ∑DEHP concentrations with overweight/obese status provides indirect 
evidence that MCPP associations are not strongly confounded by dietary sources of high 
molecular weight phthalates exposures.
Associations by race/ethnicity must be interpreted with caution. Because over 80% of the 
non-Hispanic white children in the study sample were HOME Study participants, differences 
in associations among white compared to black or Hispanic children may reflect differences 
in unmeasured characteristics of the HOME population. HOME Study mothers were older 
and more educated and their children were leaner compared to the other two cohorts, leading 
to potential differences by cohort in the magnitude of residual or unmeasured confounding 
(e.g., environmental tobacco smoke) as well as susceptibility to obesogenic effects. In 
addition, the higher prevalence of overweight/obesity among Hispanic children may have led 
to higher odds ratios in this group since the odds ratio overestimates the risk ratio when 
outcomes are common. Hispanic participants in MSSM were primarily of Puerto Rican 
origin whereas CCCEH Hispanics were Dominican, which may explain differences in 
estimates of association among Hispanic children in MSSM compared to CCCEH. Cohort-
specific estimates among non-Hispanic black children, who were included in all three 
studies, were more comparable.
We measured phthalate metabolite concentrations in a single spot urine sample, which may 
not represent exposures throughout pregnancy because phthalates are quickly eliminated 
from the body40 and exposure to phthalates sources is likely episodic. A study of the 
variability of urinary phthalate metabolite concentrations in four spot urine samples 
collected during pregnancy (range: 5–38 weeks gestation) suggested that sources of 
exposure to some phthalates (e.g., DBPs) may be more consistent during pregnancy than 
others (e.g., DEHP).41 Given the potential for exposure misclassification, our associations 
may be biased. However, under the assumptions of monotonicity and independent, non-
differential measurement error of the exposures and outcomes, we expect that effect 
estimates are in the same directions as the true associations.42 In addition, we measured 
phthalate metabolite concentrations during late pregnancy, a potential sensitive period for 
exposure to obesogens due to rapid fetal growth and adipocyte replication.43
We restricted our analysis to early childhood because phthalate exposures may affect 
puberty,44,45 a developmental stage that is also strongly tied to BMI. Evaluating associations 
among older children is warranted to determine whether associations persist with age and to 
evaluate the timing of potential obesogenic effects with respect to puberty.
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Despite limitations noted above, this prospective study has several important strengths. We 
assessed exposures during fetal development, which is thought to be a susceptible window 
for the origins of obesity.3 Pooling data from three independent cohorts with notable 
variation in population characteristics strengthened the robustness of our findings. Pooling 
also provided a large sample size to assess heterogeneity of associations by hypothesized 
modifying factors. Although we tested a relatively large number of associations, we 
employed a conservative Bayesian modeling approach that is robust to multiple testing bias. 
We minimized bias by multiply imputing missing covariate data and controlling for 
confounding among correlated phthalate metabolites. Finally, we conducted sensitivity 
analyses to explore potential bias from loss to follow-up.
In conclusion, we observed a positive association of prenatal urinary concentrations of 
MCPP, a non-specific metabolite of several phthalates, with overweight/obese status in 
children aged 4 to 7 years. Our findings do not suggest that prenatal urinary concentrations 
of other phthalate metabolites are associated with overweight/obesity. Indeed, we observed 
inverse associations of MEP, the main metabolite of DEP, and ∑DEHP with BMI z-scores 
among girls, indicating that exposure to DEP or DEHP may alter physical development. 
However, we cannot rule out confounding (e.g., from other environmental obesogens) as an 
alternative explanation to our findings.
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Figure 1. 
Posterior mean of odds ratios and 95% credible intervals for the association of a one 
standard deviation increase in natural log urinary MCPP concentrations with overweight/
obese status among children aged 4 to 7 years (N=707; 1,416 follow-up visits), overall and 
by child’s sex and race/ethnicity. Associations estimated in multiple metabolite logistic 
mixed effects regression models adjusted for cohort, maternal race/ethnicity, maternal age at 
delivery, maternal education, maternal work status during pregnancy, maternal pre-
pregnancy BMI, maternal height, gestational weight gain, maternal smoking during 
pregnancy, natural log creatinine, calendar date of urine collection, parity, child’s sex, 
breastfeeding, and months of age at follow-up.
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Figure 2. 
Posterior mean of beta coefficients and 95% credible intervals for the association of a one 
standard deviation increase in natural log urinary MEP concentrations with BMI z-scores 
among children aged 4 to 7 years (N=707; 1,416 follow-up visits), overall and by child’s sex 
and race/ethnicity. Associations estimated in multiple metabolite linear mixed effects 
regression models adjusted for cohort, maternal race/ethnicity, maternal age at delivery, 
maternal education, maternal work status during pregnancy, maternal pre-pregnancy BMI, 
maternal height, gestational weight gain, maternal smoking during pregnancy, natural log 
creatinine, calendar date of urine collection, parity, child’s sex, breastfeeding, and months of 
age at follow-up.
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Table 1
Characteristics of the study sampleat baseline by cohort and pooled,n (%)
Characteristic MSSM CCCEH HOME Pooled
Total (N) 151 339 217 707
Maternal age at delivery (years)
  < 20 42 (28) 47 (14) 13 (6) 102 (14)
  20–24 53 (35) 121 (36) 37 (17) 211 (30)
  25–29 21 (14) 100 (30) 62 (29) 183 (26)
  ≥ 30 35 (23) 71 (21) 105 (48) 211 (30)
Race/ethnicity
  Non-Hispanic white 31 (21) 0 (0) 135 (62) 166 (23)
  Non-Hispanic black 41 (27) 120 (35) 69 (32) 230 (33)
  Hispanic 76 (50) 219 (65) 4 (2) 299 (42)
  Other 3 (2) 0 (0) 9 (4) 12 (2)
Maternal education
  <High school 34 (23) 124 (37) 20 (9) 178 (25)
  High school or GED 34 (23) 126 (37) 27 (12) 187 (26)
  Some college 45 (30) 74 (22) 64 (29) 183 (26)
  ≥ College degree 38 (25) 15 (4) 106 (49) 159 (22)
Mother worked during pregnancy (yes) 92 (61) 199 (59) 181 (83) 472 (67)
Parity (multiparous) 0 (0) 188 (55) 117 (54) 305 (43)
Maternal smoking during pregnancy (yes) 26 (17) 0 (0) 22 (10) 48 (7)
Pre-pregnancy body mass index (kg/m2)
  < 18.5 9 (6) 16 (5) 7 (4) 32 (5)
  18.5–24.9 90 (60) 170 (51) 72 (43) 332 (51)
  25–29.9 37 (25) 75 (23) 48 (29) 160 (25)
  ≥ 30 15 (10) 70 (21) 40 (24) 125 (19)
  Missing 0 8 50 58
Gestational weight gain (lb)
  < 25 21 (16) 77 (25) 75 (45) 173 (29)
  25–34.9 38 (29) 79 (26) 38 (23) 155 (26)
  35–44.9 26 (20) 73 (24) 35 (21) 134 (22)
  ≥ 45 45 (35) 74 (24) 19 (11) 138 (23)
  Missing 21 36 50 107
Year of urine collection
  1998–2000 133 (88) 94 (28) 0 (0) 227 (32)
  2001–2003 18 (12) 125 (37) 26 (12) 169 (24)
  2004–2006 0 (0) 120 (35) 191 (88) 311 (44)
Child's sex (male) 80 (53) 161 (47) 94 (43) 335 (47)
Breastfed (ever) 94 (63) 256 (76) 176 (81) 526 (75)
  Missing 1 4 1 6
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Columbia Center for Children’s Environmental Health (CCCEH), Health Outcomes and Measures of the Environment Study (HOME), Mount 
Sinai School of Medicine Center for Children’s Environmental Health (MSSM)
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Table 2
Percentof children in the study sample classified as overweight/obese by age at follow-up (N=707; 1,416 
follow-up visits)
Group/category
Age (years)
4 (n = 420) 5 (n = 361) 6 (n = 258) 7 (n = 377)
Overall 28 26 38 36
Cohort
  MSSM 35 30 28 36
  CCCEH 36 35 47 44
  HOME 17 19 0a 21
Child’s sex
  Girls 28 27 39 35
  Boys 27 25 37 37
Race/ethnicity
  Non-Hispanic white 17 16 13 15
  Non-Hispanic black 22 30 37 32
  Hispanic 43 34 44 48
  Other 13 11 33 20
Columbia Center for Children’s Environmental Health (CCCEH), Health Outcomes and Measures of the Environment Study (HOME), Mount 
Sinai School of Medicine Center for Children’s Environmental Health (MSSM)
a
Fewer than 5 children in this stratum.
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Table 3
Adjusted associations between prenatal urinary phthalate metabolite concentrations and overweight/obese 
status and body mass index (BMI) z-scores among children aged 4 to 7 years, overall and by child’s sex
Metabolite / groupa Overweight/obese
OR (95% CI)b
BMI z-score
β (95% CI)c
MEP
  Overall 0.68 (0.42, 1.1) −0.05 (−0.15, 0.05)
  Girls 0.60 (0.32, 1.1) −0.14 (−0.28, 0.00)
  Boys 0.85 (0.44, 1.7) 0.07 (−0.07, 0.21)d
MnBP
  Overall 1.0 (0.51, 2.0) 0.03 (−0.12, 0.18)
  Girls 1.3(0.55, 3.0) 0.16 (−0.06, 0.39)
  Boys 0.76 (0.30, 1.9)
−0.08 (−0.28, 0.13)d
MiBP
  Overall 0.84 (0.44, 1.6) 0.01 (−0.14, 0.15)
  Girls 0.92 (0.41, 2.0) −0.07 (−0.26, 0.13)
  Boys 0.67 (0.27, 1.6) 0.02 (−0.18, 0.22)
MCPP
  Overall 2.1 (1.2, 4.0) −0.02 (−0.15, 0.11)
  Girls 2.8 (1.4, 6.0) 0.06 (−0.11, 0.23)
  Boys 1.5 (0.66, 3.7) −0.09 (−0.28, 0.09)
MBzP
  Overall 0.63 (0.34, 1.2) −0.07 (−0.20, 0.06)
  Girls 0.66 (0.31, 1.4) −0.09 (−0.27, 0.09)
  Boys 0.69 (0.29, 1.6) −0.04 (−0.22, 0.15)
∑DEHP
  Overall 0.87 (0.53, 1.4) −0.04 (−0.15, 0.06)
  Girls 0.68 (0.36, 1.3) −0.12 (−0.27, 0.02)
  Boys 1.2(0.59, 2.4) 0.04 (−0.11, 0.19)d
Associations per standard deviation increase in natural log phthalate metabolite concentrations estimated in multiple metabolite logistic 
(overweight/obese) or linear (BMI z-score) mixed effects regression models, adjusted for cohort, maternal race/ethnicity, maternal age at delivery, 
maternal education, maternal work status during pregnancy, maternal pre-pregnancy BMI, maternal height, gestational weight gain, maternal 
smoking during pregnancy, natural log creatinine, calendar date of urine collection, parity, breast feeding, months of age at follow-up, and for 
overall models, child’s sex.
aNumber of children/number of follow-up visits for each group: 707/1,416 (overall), 372/756 (girls), and 335/660 (boys).
b
Posterior mean of odds ratios (95% credible intervals).
c
Posterior mean of beta coefficients (95% credible intervals).
d
Met criteria for heterogeneity compared to girls.
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Table 4
Adjusted associations between prenatal urinary phthalate metabolite concentrations and overweight/obese 
status and body mass index (BMI) z-scores among children aged 4 to 7 yearsby race/ethnicity
Metabolite / groupa Overweight/obese
OR (95% CI)b
BMI z-score
β (95% CI)c
MEP
  Non-Hispanic white 0.74 (0.27, 2.0) 0.01 (−0.19, 0.21)
  Non-Hispanic black 0.69 (0.34, 1.4) −0.05 (−0.21, 0.12)
  Hispanic 0.62 (0.28, 1.3) −0.08 (−0.25, 0.09)
MnBP
  Non-Hispanic white 1.1 (0.32, 3.9) 0.04 (−0.23, 0.32)
  Non-Hispanic black 1.1(0.43, 2.6) 0.00 (−0.27, 0.26)
  Hispanic 0.85 (0.30, 2.5) 0.04 (−0.21, 0.29)
MiBP
  Non-Hispanic white 1.0 (0.32, 3.1) −0.02 (−0.26, 0.22)
  Non-Hispanic black 0.55 (0.22, 1.4) −0.04 (−0.32, 0.25)
  Hispanic 0.72 (0.27, 1.9) 0.01 (−0.22, 0.25)
MCPP
  Non-Hispanic white 1.2(0.35, 3.9) −0.13 (−0.39, 0.13)
  Non-Hispanic black 1.8(0.76, 4.2) 0.00 (−0.25, 0.24)
  Hispanic 3.7(1.6, 9.1)d 0.08 (−0.11, 0.27)
MBzP
  Non-Hispanic white 0.74 (0.22, 2.5) −0.16 (−0.42, 0.10)
  Non-Hispanic black 0.58 (0.25, 1.4) −0.08 (−0.32, 0.16)
  Hispanic 0.63 (0.26, 1.5) −0.01 (−0.21, 0.18)
∑DEHP
  Non-Hispanic white 1.4 (0.58, 3.6) 0.10 (−0.09, 0.29)
  Non-Hispanic black 1.0 (0.46, 2.1) −0.04 (−0.25, 0.16)
  Hispanic 0.59 (0.27, 1.3) −0.14 (−0.31, 0.03)
Associations per standard deviation increase in natural log phthalate metabolite concentrations estimated in multiple metabolite logistic 
(overweight/obese) or linear (BMI z-score) mixed effects regression models,adjusted for cohort, maternal age at delivery, maternal education, 
maternal work status during pregnancy, maternal pre-pregnancy BMI, maternal height, gestational weight gain, maternal smoking during 
pregnancy, natural log creatinine, calendar date of urine collection, parity, child’s sex, breast feeding, and months of age at follow-up.
aNumber of children/number of follow-up visits for each group: 166/358 (non-Hispanic white), 230/463 (non-Hispanic black), and 299/570 
(Hispanic).
b
Posterior mean of odds ratios (95% credible intervals).
c
Posterior mean of beta coefficients (95% credible intervals).
d
Met criteria for heterogeneity compared to non-Hispanic blacks.
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